Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938957 | 0.86 | MAPK14 (0.39) | TMPRSS4CYP3A4RAB9ACYP1A2CYP2D6 | |
| SCHEMBL11626984 | 0.84 | CYP3A4 (0.38) | TMPRSS4AKR1B10AKR1C4AKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL11626989 | 0.83 | CYP3A4 (0.49) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL19506269 | 0.83 | ADRB2 (0.35) | TMPRSS4AKR1B10AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL31591119 | 0.82 | TMPRSS4 (0.41) | TMPRSS4AKR1B10AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL14976789 | 0.81 | TMPRSS4 (0.34) | TMPRSS4AKR1B10AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL23526580 | 0.81 | KIF11 (0.38) | TMPRSS4AKR1C3AKR1C2MAPTCFTR | |
| SCHEMBL29945921 | 0.81 | KIF11 (0.38) | TMPRSS4AKR1C3AKR1C2MAPTCFTR | |
| SCHEMBL23301033 | 0.81 | CES2 (0.44) | AKR1C3AKR1C2MAPTCFTRCYP2C19 | |
| SCHEMBL29656849 | 0.81 | CES2 (0.44) | AKR1C3AKR1C2MAPTCFTRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186830-B2 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1474424-A4 | TRICYCLIC 2-PYRIMIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6844340-B2 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040266778-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | TARBY CHRISTINE M | 2004-12-30 | — | — | US | disclosed |
| EP-1474424-A1 | TRICYCLIC 2-PYRIMIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030162800-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003062238-A1 | TRICYCLIC 2-PYRIMIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162800-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | TYMP, TYMS, DPYD | TMPRSS4 128/4885AKR1B10 1608/4885AKR1C4 772/4885 |
| US-20040266778-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | TYMP, TYMS, DPYD | TMPRSS4 128/4885AKR1B10 1608/4885AKR1C4 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.